• Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming.Cell Stem Cell, Volume 10, 1, 16-28, 6 January 2012
• Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction.PNAS Jan 23, 2012
• Células madre de cordón umbilical, una puerta abierta al tratamiento de la diabetes tipo I.Josep-Maria Pujal, PhD
• Muscle : a source of progenitor cells for bone fracture healing.BMC Medicine 2011
• The King is Dead, Long Live the King: Entering A New Era of Stem Cell Research.Journal of Translat. Med. 2011, 9:218
• Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.R Bolli.Lancet 2011
• Evaluation of the Delivery of Mesenchymal Stem Cells into the Root Canal Space of Necrotic Immature Teeth after Clinical Regenerative Endodontic Procedure.Clinical Research 2011
• Noninvasive cell-tracking methods.Nature Reviews Clinical Oncology. November 2011
• Bone Marrow Stem Cell Derived Paracrine Factors for Regenerative Medicine: Current Perspectives and Therapeutic Potential.Bone Marrow Res. 2011
• One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133+ Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction.Bone Marrow Res. 2011

Authors
Paul W. Burridge, Gordon Keller, Joseph D. Gold, Joseph C. Wusend

Summary
Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts, highlighting potential applications and future challenges.